t
| TIDM | AMS |
| Share Price | 280.50p-0.53% |
| Market Cap | £615.99m |
| Date | 23 Mar 2022 |
| Time | 15:46:04 |
| Category | Director/PDMR dealings |
| ID | 8057F |
|
|
23 March 2022 |
("AMS", the "Company" or the "Group")
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 18 March 2022 that on the same day Chris Meredith, who is a Director and PDMR, had sold 7,200 Ordinary Shares of 5p held on his behalf and 5,800 Ordinary Shares of 5p held on behalf of Ingrid Meredith, a PCA of Chris Meredith, both in the name of Platform Securities Nominees Limited ("Nominee"), at a price of 286.5p per Ordinary Share.
The Company was also informed that at the same time Individual Savings Accounts ("ISA's") held in the name of Chris Meredith purchased 7,200 Ordinary Shares of 5p at a price of 286.7p per Ordinary Share and ISA's held in the name of Ingrid Meredith purchased 5,800 Ordinary Shares of 5p at a price of 286.7p per Ordinary Share.
The number of shares, and the beneficial ownership of the shares, held by Chris Meredith and Ingrid Meredith remains unchanged.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Chris Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: Director/PDMR |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 7,200 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 7,200 Ordinary Shares of 5p by an ISA held in the name of Chris Meredith |
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 7,200 Aggregated price: 286.5p |
||||||
|
e) |
Date of the transaction: 18/03/2022 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a) |
Name: Ingrid Meredith |
||||||
2. |
Reason for the notification |
||||||
|
a) |
Position/status: PCA of Chris Meredith |
||||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||||
|
b) |
Nature of the transactions: · Sale of 5,800 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 5,800 Ordinary Shares of 5p into ISA's held in the name of Ingrid Meredith |
||||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 5,800 Aggregated price: 286.5p |
||||||
|
e) |
Date of the transaction: 18/03/2022 |
||||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
- End -
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Matthew Cole |
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Gary Clarence |
|
|
|
|
|
HSBC Bank PLC (Broker) |
Tel: 44 (0) 20 7991 8888 |
|
Sam McLennan / Joe Weaving / Stephanie Cornish |
|
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made three acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.